• Parkinson’s Research

  First PD Patient Dosed with VY-AADC in RESTORE-1 Phase 2 Trial

  Posted by Forum Moderator on December 17, 2018 at 6:17 pm

  Voyager Therapeutics has started dosing its VY-AADC gene therapy in the RESTORE-1 trial for patients with therapy-resistant Parkinson’s disease. Read more about this therapy here.

  What are your thoughts on this news?

  replied 7 years, 3 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply